Your browser doesn't support javascript.
loading
Epidemiological Study of Malignant Paediatric Liver Tumours in Denmark 1985-2020.
Nissen, Thomas N; Rechnitzer, Catherine; Albertsen, Birgitte K; Borgwardt, Lotte; Christensen, Vibeke B; Fallentin, Eva; Hasle, Henrik; Johansen, Lars S; Maroun, Lisa L; Nissen, Karin B; Rasmussen, Allan; Rathe, Mathias; Rosthøj, Steen; Schultz, Nicolai A; Wehner, Peder S; Jørgensen, Marianne H; Brok, Jesper.
Afiliación
  • Nissen TN; Department of Paediatrics and Adolescent Medicine, Rigshospitalet, Copenhagen University Hospital, 2100 Copenhagen, Denmark.
  • Rechnitzer C; Department of Paediatrics and Adolescent Medicine, Rigshospitalet, Copenhagen University Hospital, 2100 Copenhagen, Denmark.
  • Albertsen BK; Department of Paediatrics and Adolescent Medicine, Aarhus University Hospital, 8200 Aarhus, Denmark.
  • Borgwardt L; Department of Clinical Medicine, Faculty of Health, Aarhus University, 8200 Aarhus, Denmark.
  • Christensen VB; Department of Radiology, Rigshospitalet, Copenhagen University Hospital, 2100 Copenhagen, Denmark.
  • Fallentin E; Department of Paediatrics and Adolescent Medicine, Rigshospitalet, Copenhagen University Hospital, 2100 Copenhagen, Denmark.
  • Hasle H; Department of Radiology, Rigshospitalet, Copenhagen University Hospital, 2100 Copenhagen, Denmark.
  • Johansen LS; Department of Paediatrics and Adolescent Medicine, Aarhus University Hospital, 8200 Aarhus, Denmark.
  • Maroun LL; Department of Paediatric Surgery, Rigshospitalet, Copenhagen University Hospital, 2100 Copenhagen, Denmark.
  • Nissen KB; Department of Pathology, Rigshospitalet, Copenhagen University Hospital, 2100 Copenhagen, Denmark.
  • Rasmussen A; Department of Paediatrics and Adolescent Medicine, Aarhus University Hospital, 8200 Aarhus, Denmark.
  • Rathe M; Department of Surgery and Transplantation, Rigshospitalet, Copenhagen University Hospital, 2100 Copenhagen, Denmark.
  • Rosthøj S; Department of Paediatric Haematology and Oncology, H. C. Andersen Children's Hospital, Odense University Hospital, 5000 Odense, Denmark.
  • Schultz NA; Department of Paediatrics and Adolescent Medicine, Aalborg University Hospital, 9000 Aalborg, Denmark.
  • Wehner PS; Department of Surgery and Transplantation, Rigshospitalet, Copenhagen University Hospital, 2100 Copenhagen, Denmark.
  • Jørgensen MH; Department of Paediatric Haematology and Oncology, H. C. Andersen Children's Hospital, Odense University Hospital, 5000 Odense, Denmark.
  • Brok J; Department of Paediatrics and Adolescent Medicine, Rigshospitalet, Copenhagen University Hospital, 2100 Copenhagen, Denmark.
Cancers (Basel) ; 15(13)2023 Jun 26.
Article en En | MEDLINE | ID: mdl-37444465
ABSTRACT

BACKGROUND:

Malignant liver tumours in children are rare and national outcomes for this tumour entity are rarely published. This study mapped paediatric liver tumours in Denmark over 35 years and reported on the incidence, outcomes and long-term adverse events.

METHODS:

We identified all liver tumours from the Danish Childhood Cancer Registry and reviewed the case records for patient and tumour characteristics, treatment and clinical outcome.

RESULTS:

We included 79 patients in the analyses. Overall crude incidence was ~2.29 per 1 million children (<15 yr) per year, with 61 hepatoblastomas (HB), 9 hepatocellular carcinomas and 9 other hepatic tumours. Overall 5-year survival was 84%, 78% and 44%, respectively. Nine patients had underlying liver disease or predisposition syndrome. Seventeen children underwent liver transplantation, with two late complications, biliary stenosis and liver fibrosis. For HB, age ≥ 8 years and diagnosis prior to 2000 were significant predictors of a poorer outcome. Adverse events included reduced renal function in 10%, reduced cardiac function in 6% and impaired hearing function in 60% (19% needed hearing aids). Behavioural conditions requiring additional support in school were registered in 10 children.

CONCLUSIONS:

In Denmark, incidences of malignant liver tumours during the last four decades have been increasing, as reported in the literature. HB survival has improved since the year 2000 and is comparable with international results. Reduced hearing is the major treatment-related side effect and affects approximately 60% of patients.
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Cancers (Basel) Año: 2023 Tipo del documento: Article País de afiliación: Dinamarca

Texto completo: 1 Bases de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Cancers (Basel) Año: 2023 Tipo del documento: Article País de afiliación: Dinamarca